Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion

The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.

    Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

    Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.

      Seattle Genetics (SGEN) Up 8.4% Since Earnings Report: Can It Continue?

      Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates

        Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.

          Why Earnings Season Could Be Great for Seattle Genetics (SGEN)

          Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

            Seattle Genetics Adcetris Performs Well Despite Competition

            Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.

              Seattle Genetics' Adcetris Gets EU Nod for Label Expansion

              European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.

                Seattle Genetics' Adcetris sBLA Gets FDA Priority Review

                Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.

                  Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report?

                  Seattle Genetics (SGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

                    Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.

                      Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat

                      Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.

                        Is a Beat in Store for Agenus (AGEN) This Earnings Season?

                        Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.

                          Soumic Nandy headshot

                          Should You Sell Seattle Genetics (SGEN) Before Earnings?

                          Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                            Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                            Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.

                              Seattle Genetics Inks Clinical Collaborations for Cancer Drug

                              Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.

                                Seattle Genetics Begins Phase II Study of Cancer Candidate

                                Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.

                                  Cancer Space Last Week Update: Pipeline Expansion in Focus

                                  Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

                                    Company News For Oct 3, 2017

                                    companies in the news are: CALM, GE, SGEN, TSM

                                      Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

                                      Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.

                                        Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher

                                        Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.

                                          Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer

                                          Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.

                                            Bristol-Myers' Opdivo Study Meets Early Success, Stock Up

                                            Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.

                                              Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA

                                              Pfizer's (PFE) Mylotarg received FDA nod as a treatment for new or relapsed CD33-positive acute myeloid leukemia.

                                                Seattle Genetics' Adcetris Granted Priority Review by FDA

                                                Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.

                                                  Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

                                                  Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.